Lilly Asia Ventures has led a $90m series B round for Duality Biologics, which revealed it has now secured $120m altogether from backers also including WuXi Biologics.
Duality Biologics, a China-based developer of treatments for cancer and autoimmune disorders, closed a $90m series B round today led by Lilly Asia Ventures, an investment arm of pharmaceutical firm Eli Lilly.
WuXi Biologics, a contract manufacturing organisation spun off from pharmaceutical company WuXi AppTec, also took part in the round, as did Yunion Healthcare Fund, Huagai Capital, NRL Capital, Green Pine Capital Partners, Oriza Holdings and unnamed others.
DualityBio additionally revealed it has now secured $120m in funding altogether,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
